Xeris Biopharma Raises 2030 Revenue Outlook to More Than $1B
Xeris Biopharma raised its 2030 revenue outlook to more than $1 billion.
Related stories
Xeris Biopharma Reports Third-Quarter 2026 Financial Results
Xeris Biopharma reported third-quarter 2026 results. Total revenue increased 44% year over year to $107 million, while Recorlev net revenue increased 93% year over year.
M impact | EQUITY | Nov 05, 2026, 12:24 PM UTC
Malibu Boats Reports 1Q Sales of $252.9 Million
M impact | EARNINGS | Nov 05, 2026, 12:19 PM UTC
Korro Bio Reports Zero Revenue and $0.98 Loss in Third Quarter
Korro Bio reported no collaboration revenue in the third quarter, down from $1.1 million a year earlier, while its net loss narrowed. Lower research and development costs, primaril
M impact | EARNINGS | Nov 05, 2026, 12:14 PM UTC
News Corp Reports Revenue of $2.28B and EPS of $0.29 for 3Q 2026
News Corp said first-quarter revenue and earnings increased year over year, citing growth in Digital Real Estate Services, Book Publishing and Dow Jones. Net income also benefited
M impact | EARNINGS | Nov 05, 2026, 12:14 PM UTC
Open Text posts Q1 adjusted EPS of $1.05
Open Text reported Q1 adjusted EPS of $1.05, versus the FactSet estimate of $0.93.
M impact | EARNINGS | Nov 05, 2026, 12:14 PM UTC
Fate Therapeutics Reports 3Q 2026 Revenue of $0 and EPS of ($0.25)
The company reported no collaboration revenue, compared with revenue a year earlier, after completing performance obligations under its Ono agreement in June. Net loss narrowed as
M impact | EARNINGS | Nov 05, 2026, 12:13 PM UTC